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METHODOLOGY
Use of thin-layer chromatography 
to detect counterfeit sulfadoxine/
pyrimethamine tablets with the wrong active 
ingredient in Malawi
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Abstract 
Background: Substandard and falsified anti-malarial medicines pose a serious threat to public health, especially in 
low-income countries. Appropriate technologies for drug quality analysis in resource-limited settings are important 
for the surveillance of the formal and informal drug market. The feasibility of thin-layer chromatography (TLC) with 
different solvent systems was tested using the GPHF Minilab in a study of the quality of sulfadoxine/pyrimethamine 
tablets in Malawi.
Methods: Twenty eight samples of sulfadoxine/pyrimethamine tablets were collected from randomly selected 
health facilities of four districts of southern Malawi. A mystery shopper approach was used when collecting samples 
from illegal street vendors, and an overt approach for the other facilities. Samples were subjected to visual inspec-
tion, disintegration testing and TLC analysis. 10 samples were further investigated according to the methods of the US 
Pharmacopeia using high performance liquid chromatography (HPLC).
Results: One sample was found to be falsified, containing a mixture of paracetamol tablets and co-trimoxazole 
tablets. These had been repackaged into paper strip packs labelled as a brand of sulfadoxine/pyrimethamine. TLC with 
different solvent systems readily proved that these tablets did not comply with their declaration, and provided strong 
evidence for the active pharmaceutical ingredients which were actually contained. Full pharmacopeial analysis by 
HPLC confirmed the results suggested by TLC for this sample, and showed two further samples to be of substandard 
quality.
Conclusions: Due to the absence of the declared anti-malarial ingredients and due to the presence of other phar-
maceutical ingredients, the identified falsified medicine represents a serious health risk for the population. Thin-layer 
chromatography (TLC) using different solvent systems proved to be a powerful method for the identification of this 
type of counterfeiting, presenting a simple and affordable technology for use in resource-limited settings.
Keywords: Falsified medicines, SSFFC medicinal products, Sulfadoxine/pyrimethamine, Thin-layer chromatography, 
GPHF Minilab
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Background
Substandard and falsified antimalarial medicines pose a 
serious threat to public health. The worldwide spread of 
falsified medicines has been addressed as a “global pan-
demic”, and in this context it has been correctly empha-
sized that “diagnostics are at the heart of any successful 
epidemic response effort” [1]. Therefore, analytical meth-
ods to identify falsified medicines are essential in order to 
fight this specific pandemic.
The gold standard methods for drug quality analysis 
are defined in the leading pharmacopeias, such as the 
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International Pharmacopeia, the United States Phar-
macopeia, the British Pharmacopeia, the Pharmacopeia 
of Japan, and others. They rely primarily on high per-
formance liquid chromatography (HPLC) for analysis 
of the content of the active ingredient, of dissolution, 
and of the presence of related substances. The required 
instruments cost 50,000–100,000 $ (USA) for standard 
equipment, and more for advanced equipment [2]. They 
are complicated and delicate mechanical and electronic 
tools, requiring careful handling by trained professionals 
as well as an infrastructure including an electricity supply 
of constant voltage, very pure organic solvents, and regu-
lar maintenance by skilled technicians. For low-income 
countries, the full pharmacopeial analysis of medicines 
is a formidable challenge and can usually be achieved 
only for a limited number of samples in the national drug 
quality control laboratories. In most cases, no capac-
ity exists in such countries for the regular surveillance 
of drug quality on the various levels of the drug supply 
chain, thereby opening the possibility for substandard 
and falsified medicines to enter the market [3].
Appropriate technologies for drug analysis in resource-
limited settings would allow a more regular surveillance 
of the formal and informal drug market, aiding in the 
rapid detection of falsified medicines and potentially 
deterring criminal counterfeiters from bringing their 
products into the market. A number of such appropri-
ate analytical technologies have been reported [2–4]. Few 
of them are ready for wide-spread application. The best-
established one is thin-layer chromatography (TLC). For 
drug quality analysis in resource-limited settings, TLC 
is mostly employed in form of the Minilab™ supplied by 
the Global Pharma Health Fund (GPHF), a charity sup-
ported by the Merck pharmaceutical company [5]. The 
Minilab is a pre-assembled kit containing all analytical 
tools for the qualitative and semi-quantitative TLC analy-
sis of about 100 essential medicines, and does not require 
electricity, running water or any sophisticated infrastruc-
ture. It is supplied with a manual describing the analytical 
procedure for each drug, and only very limited training 
is required for its use. TLC analysis using the Minilab 
has been used in many studies in Africa, Asia and South 
America [6, 7]. However, also limitations of this technol-
ogy in comparison to full pharmacopeial analysis have 
been pointed out [8].
Before embarking on a larger study on the quality of 
antimalarial drugs in Malawi, the feasibility of TLC anal-
ysis was tested using samples of the anti-malarial drug 
sulfadoxine/pyrimethamine (SP) as example. In govern-
mental and church health facilities of Malawi, SP is used 
for intermittent preventive malaria treatment in preg-
nancy. Private vendors frequently sell SP also to other 
patients as a single-dose malaria therapy, despite the fact 
that artemisinin-based combination therapies are now 
recommended as first-line therapy for malaria. In the 
course of this pilot study, a falsified SP sample was identi-
fied which contained active ingredients different from the 
declared ones. TLC analysis using different solvent sys-
tems allowed not only to prove that this sample did not 
conform to its declaration, but also provided strong evi-
dence which active ingredients were actually contained. 
This demonstrates a power and versatility of TLC analy-
sis which should be considered when the relative merits 
of different analytical techniques for drug quality analysis 
are discussed. This study highlights the usefulness of TLC 
analysis especially in the case of falsified drugs which 




Out of the 13 districts of southern Malawi, four were ran-
domly selected. From each of these districts, a list of gov-
ernment health centers was obtained. From each of three 
districts, two health centres were selected randomly, and 
samples were collected from these health centres as well 
as from the respective district hospital. The fourth dis-
trict comprised one of Malawi’s larger cities. From this 
district two urban and two rural health centres were ran-
domly selected, and samples were collected from there, 
from the district health office and from the central hospi-
tal. If church-affiliated health facilities, private pharmacy 
shops, drug stores, or illegal street vendors could be 
identified nearby the selected government health facili-
ties, then drugs samples were also collected from there. 
Samples were collected by members of the Pharmacy 
Department, University of Malawi. A mystery shopper 
approach was used for the illegal street vendors, and an 
overt approach for the other facilities. The mystery shop-
per stated that he had been asked by friends in his vil-
lage to buy this medicine for them. Samples of 150 tablets 
were collected if available, otherwise smaller numbers. If 
medicines with generic and brand name were available, 
the brand name medicine was sampled. If several brand 
name medicines were available, the most expensive brand 
name medicine was sampled. In most sites, however, only 
a single type of sulfadoxine/pyrimethamine tablets was 
available. Samples were transported to the Pharmacy 
Department, College of Medicine, Blantyre, within 48 h, 
and stored below 25 °C until analysis.
Visual inspection, disintegration testing and testing 
for uniformity of mass of dosage units
The external packaging, primary packaging and (if avail-
able) package leaflets were inspected, including batch 
number and expiry dates. The tablets were visually 
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inspected, especially for undamaged, unaltered surfaces 
and colour uniformity. Disintegration testing for instant-
release oral dosage forms was carried out according to 
the manual of the GPHF Minilab [9]; in short, six tablets 
were kept in water at 37 °C under occasional shaking or 
stirring, and complete disintegration within 30 min was 
confirmed. For uniformity of mass of dosage unit, the 
exact weight of 20 tablets was determined; acceptable 
deviations were: up to ±5 % in at least 18 tablets, and up 
to ±10 % in no more than two tablets.
Thin‑layer chromatographic (TLC) testing
TLC testing was done according to the procedure given 
by the manual of the GPHF Minilab for sulfadoxine 
(including SP formulations) [9]. From each sample, three 
tablets were analysed individually. In short, each tablet 
was crushed to a fine powder and extracted with 20 ml 
methanol by vigorous shaking for 3 min. After sedimen-
tation of undissolved residues, 1  ml of the supernatant 
was removed and diluted with 3  ml methanol. Using 
a microcapillary, 2  µl of this solution were applied to a 
TLC plate (Merck silica gel 60 F254, 0.2  mm thickness, 
5 × 10 cm). Authentic standard solutions of sulfadoxine/
pyrimethamine with known concentrations were applied 
as comparison. The plate was developed in a solvent sys-
tem of ethyl acetate:methanol 15:5 for approximately 
15  min. After drying off the residual solvent, the active 
pharmaceutical ingredients were visualized first under 
UV light (254  nm), and subsequently by iodine vapour. 
The results were documented using an inexpensive digi-
tal camera (Canon PowerShot SX600 HS).
For comparison to authentic paracetamol and co-tri-
moxazole samples, the solvent systems given by the man-
ual of the GPHF Minilab for analysis of paracetamol[9], 
pyrimethamine [10] and co-trimoxazole [9] were used, i.e. 
acetone:toluene:acetic acid 10:10:0.5 (for the experiment 
depicted in Fig. 2b); ethyl acetate:methanol:acetone:conc.
aqueous ammonia 12:6:2:0.5 (Fig.  2c); ethyl 
acetate:methanol 15:5 (Fig. 2d).
HPLC analysis according to the United States 
Pharmacopeia (USP)
Following the methods specified in USP38-NF33, iden-
tification of the active ingredients by TLC and HPLC, 
HPLC analysis (=assay) for the content of sulfadoxine 
and pyrimethamine, analysis for uniformity of dosage 
units with respect to the content of the active ingredi-
ents, and analysis of their dissolution was carried out in 
the WHO-prequalified drug quality control laboratory 
of the Mission for Essential Drugs and Supplies, Nairobi, 
Kenya. HPLC analysis for sulfadoxine and pyrimeth-
amine was carried out using a Gemini 5  µm C6-Phenyl 
110Å HPLC column 250 × 4.6 mm (Phenomenex, USA) 
and an isocratic solvent system of 0.1  % aqueous phos-
phoric acid:acetonitrile 83:17, flow rate 1.2 ml/min. The 
wavelength for UV detection was 230 nm. For the iden-
tification of paracetamol and co-trimoxazole, the respec-
tive methods of USP38-NF33 for those drugs were used.
Ethical approval
This study was approved by the College of Medicine 
Research and Ethics Committee, University of Malawi.
Results
Sample collection
Twenty eight samples of sulfadoxine 500  mg/pyrimeth-
amine 25  mg tablets were collected in four districts in 
southern Malawi. 15 were collected from government 
health facilities, seven from church-affiliated health facili-
ties, four from private pharmacies and drug stores, and two 
from illegal street vendors. 21 of the samples were found 
to be distributed under the generic name “sulfadoxine/
pyrimethamine”, and seven under brand names. According 
to the information on the packaging, the samples had been 
produced by six different manufacturers, with 18 sam-
ples produced in in India (by two different manufactures), 
three in China, three in Tanzania, two in Cyprus and two 
in Malawi. Comparison with the records of the Pharmacy, 
Medicines and Poisons Board, i.e. the national drug regu-
latory agency of Malawi, showed that the SP tablets from 
five of the manufacturers were registered in Malawi, but the 
tablets from one of the manufactures were not. The non-
registered type represented the most common SP prepara-
tion collected in government and church-affiliated health 
facilities, accounting for 17 of the 28 samples.
Visual inspection
Only a single sample clearly failed visual inspection. It was 
purchased from an illegal street vendor and was sold in 
an opened, apparently genuine cardboard box labelled 
“Novidar (SP)”, a brand name of SP manufactured and 
sold by the Malawian manufacturer Pharmanova Ltd. 
The cardboard box contained paper strip packs labelled 
“Novidar (SP)” which, however, were found to be of two 
different kinds (Fig. 1). One (hereafter called type N) was 
stamped with the same batch number and expiry date 
as given on the outer packaging (i.e. the cardboard box). 
The other one was stamped with two dates  (“27/04/2010” 
and “20/11/2015”), different from those given on the 
outer package. These paper strip packs were made from a 
thinner type of paper than those of type N. A part of the 
tablets in these strip packs had apparently adsorbed mois-
ture. Upon opening of the strip packs, some tablets were 
found to stick to the paper, and to break easily.
Fifteen paper strips of this kind were contained in 
this sample. Although they were all uniform in their 
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appearance and stamp, they were found to contain two 
different kinds of tablets (Fig.  1). One (hereafter called 
type X) did not carry an imprint on its front side. The 
other one (hereafter called type Y) was imprinted with 
the letters “UCL”. In contrast, the tablets with the paper 
strips of type N were imprinted with “Novidar SP” on the 
front side, which is consistent with the genuine product 
of Pharmanova Ltd.
Thin‑layer chromatographic analysis
The tablets of types N, X and Y were subjected to thin-
layer chromatographic (TLC) analysis according to the 
procedure given in the manual of the GPHF Minilab for 
sulfadoxine/pyrimethamine tablets (see Methods sec-
tion). An authentic standard of sulfadoxine 500  mg/
pyrimethamine 25 mg was used for comparison. Detec-
tion was carried out first with UV light (254  nm), then 
with iodine staining. The result is shown in Fig. 2a. The 
complete analytical procedure was repeated again, start-
ing from different tablets. The results were identical to 
those shown in Fig. 2a.
Both in the first and the second analysis, the tab-
lets of type N showed spots identical in Rf value and 
intensity to those of sulfadoxine and pyrimethamine 
in the authentic standard. This strongly indicates that 
this product contains the declared active ingredients 
in the declared amounts, and most likely represents 
the original product “Novidar (SP)” of the Malawian 
manufacturer Pharmanova Ltd. Type X showed no 
spots identical in Rf value to those of sulfadoxine and 
pyrimethamine. This proves the absence of relevant 
quantities of both active principles in this product. 
Instead, TLC analysis showed another compound, giv-
ing a spot of an Rf value slightly lower than sulfadox-
ine. The different Rf value, and the different response 
to iodine staining (Fig. 2a), prove that this compound is 
different from sulfadoxine.
Type Y showed no spot identical in Rf value to that of 
pyrimethamine from the authentic standard. This proves 
the absence of relevant quantities of pyrimethamine in 
this product. However, TLC analysis did show a spot 
similar in Rf value and intensity to that of sulfadoxine, 
indicating the presence either of sulfadoxine or of a com-
pound with similar chromatographic behaviour. Further-
more, TLC analysis showed a spot of a further compound, 
with an Rf value clearly lower than pyrimethamine.
The imprint “UCL” is used by the Kenyan pharmaceuti-
cal manufacturer Universal Corporations Ltd. Therefore, 
tablets of type Y were compared the with drugs from this 
manufacturer. And indeed, Sulfran™ tablets (co-trimox-
azole 480  mg) marketed by UCL in Malawi were found 
to be perfectly identical in shape, size and imprint to the 
tablets of type Y. It was furthermore speculated that type 












Tablets imprinted with „Novidar SP“
Type Y: imprinted with „UCL“
Type X: no imprint
front side: back side:front side: back side:
Fig. 1 Primary packaging and tablets of Novidar (SP)™ and of the falsified samples type X and type Y
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To test these hypotheses, the tablets were further analy-
esed in comparison to authentic paracetamol 500 mg tab-
lets and to co-trimoxazole 480 mg tablets using the TLC 
solvent systems given in the manual of the GPHF Minilab 
for paracetamol (Fig. 2b) for pyrimethamine (Fig. 2c) and 
for sulfamethoxazole and co-trimoxazole (Fig. 2d). In all 
three solvent systems, type X showed identical results as 
paracetamol 500 mg tablets, and type Y showed identical 
results as co-trimoxazole 480 mg. Both type X and type Y 
proved to be clearly different from their declared content, 
i.e. sulfadoxine/pyrimethamine.
Visual inspection, TLC analysis and disintegration testing 
of further samples
Of the 27 further SP samples collected in this study, 
one showed chippings upon visual inspection (hereafter 
called sample Z). Otherwise, all samples passed visual 
inspection, as well as TLC analysis and disintegration 
testing, performed according to the Minilab manual, and 
also testing of the uniformity of mass of dosage units.
Full pharmacopeial analysis including High‑Performance 
Liquid Chromatography (HPLC)
Ten samples were subjected to a full pharmacopeial 
analysis according to the methods of the United States 
Pharmacopeia (USP) in the WHO-prequalified drug 
quality control laboratory of the Mission for Essen-
tial Drugs and Supplies (MEDS) in Nairobi, Kenya. 
These included the sample containing a mixture of 
tablets of types X and Y, the sample Z showing chip-
pings, and eight further, randomly selected samples. 
While authentic sulfadoxine and pyrimethamine 
standards showed HPLC retention times of 8.24 and 
3.26 min, respectively, tablets of type X showed a peak 
at 3.43 min (paracetamol), and tablets of type Y showed 
peaks at 9.07  min (sulfamethoxazole) and 2.11  min 
(trimethoprim), proving that these tablets did not con-
tain the declared active ingredients. Using authentic 
standards for paracetamol and co-trimoxazole and the 
appropriated USP methods for these drugs, the tab-
lets of type X and type Y were confirmed to represent 
UV light, 254 nm
Start
S N X Y s
Iodine stain
S N X Y s
UV light, 254 nm Iodine stain
N P X C Y
N P X C Y
N P X C Y N P X C Y
Trimethoprim
Sulfamethoxazole













Fig. 2 TLC analysis of Novidar (SP)™ tablets (labled as N) and of the falsified samples type X and type Y (labeled as X and Y). a Comparison to an 
authentic standard of sulfadoxine 500 mg/pyrimethamine 25 mg (S) and to an authentic standard containing only 80 % of these amounts (s). b–d 
Comparison to paracetamol 500 mg (P) and co-trimoxaxole 480 mg (C), using different TLC solvent systems
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paracetamol 500 mg tablets and co-trimoxazole 480 mg 
tablets.
The sample with chippings (sample Z) failed pharma-
copeial analysis both for sulfadoxine content (71.8  % of 
declared content) and for dissolution of sulfadoxine and 
pyrimethamine (55.5 % and 52 % dissolution in 30 min). 
One further sample failed dissolution for pyrimethamine 
(37.6  % dissolution in 30  min). Of the total of 10 sam-
ples subjected to analysis according to the USP, therefore 
seven passed the analysis in all aspects.
Discussion
This study identified a sample labeled as sulfadoxine 
500 mg/pyrimethamine 25 mg tablets which was sold by 
an illegal street vendor in Malawi and which contained, 
instead of the declared content, a mixture of paraceta-
mol 500  mg tablets and co-trimoxazole 480  mg tablets. 
Apparently, paracetamol and co-trimoxazole tablets had 
been intentionally mislabelled for reasons of profit. In 
the International Drug Price Indicator Guide 2014 [11], 
the prices of one tablet of paracetamol 500  mg and co-
trimoxazole 480 mg are given as 0.48 and 1.26 US cents, 
respectively, in international bulk procurement. In con-
trast, the price of sulfadoxine 500  mg/pyrimethamine 
25  mg is given as 7.17 US cents. A similar difference 
exists in the retail prices of these medications in Malawi. 
In the price list of the Medical Aid Society of Malawi 
(MASM), they are given as 15, 20 and 80 Malawi Kwa-
cha, corresponding to 2.60, 3.47 and 13.9 US cents per 
tablet, respectively (John Mponda, MASM, personal 
communication).
Due to the absence of the declared anti-malarial ingre-
dients, and due to the presence of other pharmaceutical 
ingredients with their own potential risks and adverse 
effects, these falsified medicines represent a serious 
health risk for the population. The national drug regu-
latory agency, i.e. the Pharmacy, Medicines and Poi-
sons Board of Malawi (PMPB) was informed about this 
finding.
For poor-quality and falsified medicines there is yet 
no universally accepted terminology. The World Health 
Organization (WHO) summarily addresses them as 
“substandard/spurious/falsely-labelled/falsified/coun-
terfeit (SSFFC)” medicinal products. Several authors 
classify them into three main categories [1]: (1) falsi-
fied medicines, resulting from intentional fraudulent 
manufacturing; (2) substandard medicines, resulting 
from unintentional errors caused in manufacturing; and 
(3) degraded medicines which become of poor quality 
due to poor storage or transport conditions, or to poor 
handling. Two samples in this study failed pharmaco-
peial analysis, both due to insufficient dissolution and 
one also for insufficient content of an active ingredi-
ent. They may belong to the second or third category 
mentioned above. Only one of them (sample Z) showed 
defects already in visual inspection, but both passed 
TLC analysis and disintegration testing following the 
procedures of the GPHF Minilab manual [9]. This is 
consistent with earlier results that full pharmacopeial 
analysis is required for reliable detection of substandard 
or degraded medicines [8].
Falsified medicines, the first category mentioned above, 
may be further subdivided according to their compo-
sition and the resulting risk which they pose for public 
health: (a) falsified medicines which contain the declared 
active ingredients and are of acceptable quality; (b) fal-
sified medicines which contain insufficient amounts of 
active ingredient or are of insufficient quality; (c) falsi-
fied medicines which contain no active ingredient; (d) 
falsified medicines which contain other active ingredi-
ent than the declared ones. The latter category presents 
the highest threat to public health. The present finding of 
an SP sample in Malawi which contains not the declared 
active pharmaceutical ingredients but different ones falls 
into this category. For small gangs of criminals the pro-
cedure of misappropriating drugs, relabelling them as 
more expensive medicines and selling them with higher 
profit may become increasingly attractive: since there are 
no production costs other than for the repackaging, this 
procedure probably offers a higher profit margin than any 
other method of drug counterfeiting. Therefore, wide-
spread surveillance for that kind of counterfeiting may be 
desirable, especially in poor countries where this type is 
most likely to occur.
The TLC experiments using different solvent sys-
tems shown in Fig.  2 show the power and versatility of 
thin-layer chromatography in the identification of falsi-
fied medicines which contain the wrong active ingredi-
ent. Using only very simple equipment and inexpensive 
chemicals, these experiments not only proved that the 
investigated samples of type X and Y did not conform to 
their declaration of sulfadoxine/pyrimethamine, but also 
provided strong evidence that they actually represented 
paracetamol and co-trimoxazole tablets, respectively. To 
the best of the knowledge of the authors, no other read-
ily available analytical technology could have given this 
result with comparable cost, speed and ease.
Obviously, the simple and inexpensive TLC technology 
has limitations. Figure  2 shows that TLC analysis could 
not differentiate between the chemically quite similar 
compounds sulfadoxine and sulfamethoxazole. In con-
trast, the higher resolution power of HPLC was able to 
differentiate between these compounds, showing reten-
tion times of 8.24 and 9.07 min, respectively.
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Conclusions
Out of 28 samples of sulfadoxine/pyrimethamine tablets 
collected in Malawi, one was found not to contain the 
declared active ingredients but to represent a mixture 
of paracetamol and co-trimoxazole tablets. This type of 
counterfeiting represents a serious risk to public health. 
Thin-layer chromatography (TLC) using different solvent 
systems proved to be a powerful, affordable and simple 
method for the identification of this sample, presenting 
an appropriate technology for drug analysis in resource-
limited settings.
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